The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...

Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

has accepted for review the New Drug Application (NDA) for its novel Bumetanide Nasal Spray (RSQ-777). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

showed that 22.5% of people using esketamine nasal spray achieved remission from major depression in four weeks. Just 7.6% of people using a placebo did. The history of this drug traces back to ...

The global landscape of neurological health is undergoing a transformative moment with a pioneering nasal spray that could potentially revolutionize Alzheimer‘s disease management. As ...

MANILA (Reuters) -- The Philippines will respond favorably if Interpol is asked by the International Criminal Court to issue arrest warrants related to its probe into the former president's bloody ...

The results? A nasal spray of oxytocin significantly reduced acute feelings of loneliness in participants, especially during group therapy sessions, even months after treatment. In the study ...

has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in adults with major depressive disorder who ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...